Bausch Health Companies Inc. (BHC) stock
BHCNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/3077% below fair value
$8.35+0.10 (+1.21%)
Close on Nov 13, 2026Market cap $3.13BP/E –Yield –
Bausch Health Companies ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Bausch Health Companies's ebitda for the twelve months ending Sep 30, 2026 was $2.40B, down 23.2% year over year. For fiscal 2025 it was $3.02B, up 7.4% from the year before. Over ten years it grew -2.8% a year on average. The highest annual figure on record is $3.99B in fiscal 2015.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.02B | +7.4% |
| FY2024 | Dec 31, 2024 | $2.81B | +26.3% |
| FY2023 | Dec 31, 2023 | $2.23B | +20.5% |
| FY2022 | Dec 31, 2022 | $1.85B | -7.7% |
| FY2021 | Dec 31, 2021 | $2.00B | -20.0% |
| FY2020 | Dec 31, 2020 | $2.50B | +33.6% |
| FY2019 | Dec 31, 2019 | $1.87B | +330.3% |
| FY2018 | Dec 31, 2018 | $435.00M | -85.3% |
| FY2017 | Dec 31, 2017 | $2.96B | +28.7% |
| FY2016 | Dec 31, 2016 | $2.30B | -42.4% |
| FY2015 | Dec 31, 2015 | $3.99B | +10.5% |
| FY2014 | Dec 31, 2014 | $3.62B | +125.1% |
| FY2013 | Dec 31, 2013 | $1.61B | +50.7% |
| FY2012 | Dec 31, 2012 | $1.07B | +16.8% |
| FY2011 | Dec 31, 2011 | $912.56M | +531.9% |
| FY2010 | Dec 31, 2010 | $144.42M | -56.3% |
| FY2009 | Dec 31, 2009 | $330.41M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.27B | +37.0% |
| Q2 FY2026 | Jun 30, 2026 | $1.02B | +36.0% |
| Q1 FY2026 | Mar 31, 2026 | -$655.00M | -212.7% |
| Q4 FY2025 | Dec 31, 2025 | $764.00M | -11.7% |
| Q3 FY2025 | Sep 30, 2025 | $925.00M | +44.5% |
| Q2 FY2025 | Jun 30, 2025 | $751.00M | +6.2% |
| Q1 FY2025 | Mar 31, 2025 | $581.00M | -3.3% |
| Q4 FY2024 | Dec 31, 2024 | $865.00M | +25.2% |
| Q3 FY2024 | Sep 30, 2024 | $640.00M | +103.2% |
| Q2 FY2024 | Jun 30, 2024 | $707.00M | -2.8% |
| Q1 FY2024 | Mar 31, 2024 | $601.00M | +21.7% |
| Q4 FY2023 | Dec 31, 2023 | $691.00M | +457.3% |
| Q3 FY2023 | Sep 30, 2023 | $315.00M | -45.6% |
| Q2 FY2023 | Jun 30, 2023 | $727.00M | +43.1% |
| Q1 FY2023 | Mar 31, 2023 | $494.00M | -22.4% |
| Q4 FY2022 | Dec 31, 2022 | $124.00M | -83.0% |
| Q3 FY2022 | Sep 30, 2022 | $579.00M | -39.4% |
| Q2 FY2022 | Jun 30, 2022 | $508.00M | +279.1% |
| Q1 FY2022 | Mar 31, 2022 | $637.00M | +250.0% |
| Q4 FY2021 | Dec 31, 2021 | $730.00M | +72.6% |
| Q3 FY2021 | Sep 30, 2021 | $956.00M | +6.7% |
| Q2 FY2021 | Jun 30, 2021 | $134.00M | -70.4% |
| Q1 FY2021 | Mar 31, 2021 | $182.00M | -75.0% |
| Q4 FY2020 | Dec 31, 2020 | $423.00M | – |
| Q3 FY2020 | Sep 30, 2020 | $896.00M | +5.5% |
| Q2 FY2020 | Jun 30, 2020 | $453.00M | -42.5% |
| Q1 FY2020 | Mar 31, 2020 | $729.00M | -11.0% |
| Q4 FY2019 | Dec 31, 2019 | -$584.00M | -202.3% |
| Q3 FY2019 | Sep 30, 2019 | $849.00M | +3.5% |
| Q2 FY2019 | Jun 30, 2019 | $788.00M | +46.2% |
| Q1 FY2019 | Mar 31, 2019 | $819.00M | – |
| Q4 FY2018 | Dec 31, 2018 | $571.00M | +14.9% |
| Q3 FY2018 | Sep 30, 2018 | $820.00M | +11.4% |
| Q2 FY2018 | Jun 30, 2018 | $539.00M | -36.0% |
| Q1 FY2018 | Mar 31, 2018 | -$1.50B | -268.9% |
| Q4 FY2017 | Dec 31, 2017 | $497.00M | -42.0% |
| Q3 FY2017 | Sep 30, 2017 | $736.00M | – |
| Q2 FY2017 | Jun 30, 2017 | $842.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $885.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $857.00M | – |
See a number that looks wrong?